Loading
A phase 2/3 trial of Pembrolizumab, Gemcitabine, Cisplatin and Enfortumab vedotin in bladder & urothelial cancer, run by Vasgene Therapeutics, Inc, now recruiting.
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors is a phase 2/3 interventional study registered as NCT06493552 by Vasgene Therapeutics, Inc, with 700 participants planned, started 2025-03-15 and due to reach its primary completion in 2029-09. Interventions recorded: SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin and Enfortumab vedotin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Enfortumab vedotin, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Gemcitabine, Bladder & urothelial cancer, Cisplatin, Pembrolizumab and the tag pipeline.
Shares Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Gemcitabine, Bladder & urothelial cancer, Cisplatin, Pembrolizumab and the tag pipeline.
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/